Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LMT
8. USO
9. META
10. TLT

Go back to Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results

Myriad Genetics (MYGN) Misses Q1 EPS by 24c; Lowers Outlook

November 4, 2019 4:16 PM EST

Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of $0.08, $0.24 worse than the analyst estimate of $0.32. Revenue for the quarter came in at $186.3 million versus the consensus estimate of $202.1 million.

"We had a challenging start to fiscal year 2020 as hereditary cancer revenue accrual from small payers was impacted by the... More